• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

以皮疹为首发症状的特发性多中心Castleman病采用利妥昔单抗方案成功治疗

Successful Treatment of Idiopathic Multicentric Castleman Disease With Rash as the Initial Symptom Using a Rituximab-Based Regimen.

作者信息

Zhu Li, Liu Yi, Yu Fang, Yin Xue Jiao, Yao Qiu Mei, Meng Hai Tao, You Liang Shun, Tong Hong Yan

机构信息

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang, China.

Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, Zhejiang, China.

出版信息

J Hematol. 2024 Oct;13(5):245-249. doi: 10.14740/jh1313. Epub 2024 Oct 21.

DOI:10.14740/jh1313
PMID:39493601
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11526581/
Abstract

Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by enlarged lymph nodes and systemic inflammation, often involving multiple organ dysfunction. However, cutaneous involvement in iMCD is rare and heterogeneous, and studies on the treatment of iMCD with skin involvement are scarce. Here, we present a rare case of iMCD with prominent facial skin involvement, which showed significant improvement with rituximab-based regimen treatment.

摘要

特发性多中心Castleman病(iMCD)是一种罕见的淋巴增殖性疾病,其特征为淋巴结肿大和全身炎症,常累及多器官功能障碍。然而,iMCD累及皮肤的情况罕见且表现各异,关于伴有皮肤受累的iMCD治疗的研究也很少。在此,我们报告1例以面部皮肤显著受累为特征的罕见iMCD病例,该病例采用基于利妥昔单抗的方案治疗后有显著改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/152e/11526581/615116ffe6ab/jh-13-245-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/152e/11526581/814c60338ca1/jh-13-245-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/152e/11526581/73f57e6c4c3f/jh-13-245-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/152e/11526581/615116ffe6ab/jh-13-245-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/152e/11526581/814c60338ca1/jh-13-245-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/152e/11526581/73f57e6c4c3f/jh-13-245-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/152e/11526581/615116ffe6ab/jh-13-245-g003.jpg

相似文献

1
Successful Treatment of Idiopathic Multicentric Castleman Disease With Rash as the Initial Symptom Using a Rituximab-Based Regimen.以皮疹为首发症状的特发性多中心Castleman病采用利妥昔单抗方案成功治疗
J Hematol. 2024 Oct;13(5):245-249. doi: 10.14740/jh1313. Epub 2024 Oct 21.
2
Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.利妥昔单抗联合治疗方案治疗特发性多中心 Castleman 病的疗效。
Ann Hematol. 2018 Sep;97(9):1641-1647. doi: 10.1007/s00277-018-3347-0. Epub 2018 May 7.
3
Peculiar hyper vascular manifestations in idiopathic multicentric castleman disease without tafro syndrome: a case report.无塔夫罗综合征的特发性多中心Castleman病中的特殊高血管表现:一例报告
Ann Hematol. 2024 Dec;103(12):5929-5934. doi: 10.1007/s00277-024-06040-z. Epub 2024 Oct 14.
4
Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.病毒组捕获测序不能在局灶性和特发性多中心 Castleman 病中识别出活跃的病毒感染。
PLoS One. 2019 Jun 26;14(6):e0218660. doi: 10.1371/journal.pone.0218660. eCollection 2019.
5
Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.用司妥昔单抗治疗15年的特发性多中心Castleman病:一例报告
Ther Adv Hematol. 2022 Mar 2;13:20406207221082552. doi: 10.1177/20406207221082552. eCollection 2022.
6
[Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].[特发性多中心Castleman病的诊断与治疗新进展]
Rinsho Ketsueki. 2019;60(9):1205-1211. doi: 10.11406/rinketsu.60.1205.
7
Castleman Disease: A Rare Lymphoproliferative Disorder With Diverse Clinical Presentation, Diagnosis, and Treatment Approach.卡斯特曼病:一种临床表现、诊断及治疗方法多样的罕见淋巴增殖性疾病。
Cureus. 2024 Sep 11;16(9):e69149. doi: 10.7759/cureus.69149. eCollection 2024 Sep.
8
Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.特发性多中心 Castleman 病的新见解和治疗方法。
Blood. 2018 Nov 29;132(22):2323-2330. doi: 10.1182/blood-2018-05-848671.
9
TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?TAFRO综合征:一种综合征还是多中心Castleman病的一个亚型?
Biomedicines. 2024 Mar 14;12(3):652. doi: 10.3390/biomedicines12030652.
10
Are Patients with HHV-8 Associated Castleman Disease Successfully Treated with Rituximab at Risk of Subsequently Developing HHV-8 Negative (Idiopathic) Castleman Disease?接受利妥昔单抗成功治疗的HHV-8相关卡斯特曼病患者是否有随后发生HHV-8阴性(特发性)卡斯特曼病的风险?
Eur J Case Rep Intern Med. 2023 Jun 20;10(7):003904. doi: 10.12890/2023_003904. eCollection 2023.

本文引用的文献

1
Rituximab-bortezomib-dexamethasone induce high response rates in iMCD in clinical practice.利妥昔单抗-硼替佐米-地塞米松在临床实践中诱导 iMCD 高缓解率。
Br J Haematol. 2023 Dec;203(5):803-806. doi: 10.1111/bjh.19000. Epub 2023 Jul 23.
2
A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.一项在中国开展的采用Castleman病协作网(CDCN)标准的Castleman病全国多中心回顾性研究。
Lancet Reg Health West Pac. 2023 Mar 24;34:100720. doi: 10.1016/j.lanwpc.2023.100720. eCollection 2023 May.
3
Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
西妥昔单抗可改善特发性多中心 Castleman 病的无进展生存期。
Blood Adv. 2022 Aug 23;6(16):4773-4781. doi: 10.1182/bloodadvances.2022007112.
4
Cutaneous Plasmacytosis and Idiopathic Multicentric Castleman Disease: A Spectrum of Disease?皮肤浆细胞瘤和特发性多中心 Castleman 病:一种疾病谱?
Am J Dermatopathol. 2022 Apr 1;44(4):294-296. doi: 10.1097/DAD.0000000000002109.
5
Cutaneous Manifestations of Castleman Disease: Histopathological Characteristics and Review of Literature.Castleman 病的皮肤表现:组织病理学特征及文献复习。
Am J Dermatopathol. 2021 Dec 1;43(12):926-931. doi: 10.1097/DAD.0000000000001971.
6
Cutaneous involvement as initial presentation of multicentric plasmacytic Castleman disease.皮肤受累为多发性中心性Castleman 病的首发表现。
J Cutan Pathol. 2021 May;48(5):701-705. doi: 10.1111/cup.13964. Epub 2021 Mar 7.
7
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.国际循证共识性单中心Castleman 病诊断与治疗指南。
Blood Adv. 2020 Dec 8;4(23):6039-6050. doi: 10.1182/bloodadvances.2020003334.
8
Cutaneous manifestations of Castleman disease.卡斯特曼病的皮肤表现。
Int J Dermatol. 2020 Oct;59(10):1226-1240. doi: 10.1111/ijd.15043. Epub 2020 Jul 19.
9
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.特发性多中心 Castleman 病的国际、循证共识治疗指南。
Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.
10
Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients.Castleman病的临床特征与预后:185例中国患者的多中心研究
Cancer Sci. 2018 Jan;109(1):199-206. doi: 10.1111/cas.13439. Epub 2017 Dec 28.